Ligand Pharmaceuticals Incorporated · NASDAQ:LGND

Reardon Andrew sold 5,000 Ligand Pharmaceuticals Incorporated shares (Form 4)

Traded May 1, 2026 · Filed May 4, 2026

On May 1, 2026, Reardon Andrew (CLO & Secretary) sold 5,000 Ligand Pharmaceuticals Incorporated shares at an average US$231.31 for US$1.16M under a trading plan, leaving 41,382 shares. Filed May 4, 2026 (Form 4).

Sold
5,000 shares
Price
US$231.31 average (US$227.45 to US$234.02)
Value
US$1.16M
Holding after
41,382 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CLO & Secretary

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 1, 2026Common StockOption exercise5,000US$52.2746,382Direct
May 1, 2026Common StockSale600US$227.4545,782Direct
May 1, 2026Common StockSale932US$228.7544,850Direct
May 1, 2026Common StockSale98US$229.7144,752Direct
May 1, 2026Common StockSale370US$230.8744,382Direct
May 1, 2026Common StockSale780US$232.0443,602Direct
May 1, 2026Common StockSale1,420US$232.9242,182Direct
May 1, 2026Common StockSale800US$234.0241,382Direct

Source

View original at SEC

Related